Market Position Sandoz Canada operates as a subsidiary of a global leader in generic and biosimilar medicines with a portfolio of over 700 medicines in Canada, indicating strong scale, broad therapeutic coverage, and potential for cross-sell of biosimilars and generics to Canadian healthcare institutions.

Expansion & Innovation Recent launches including Enzeevu and a generic version of semaglutide signal an active pipeline and commitment to widening access, presenting opportunities to engage hospitals, clinics, and pharmacies seeking cost-effective biosimilar and generic options.

Key Relationships Recognition as a Top Employer and established partnerships with pharmacists, physicians, hospitals, and distributors, along with distributors’ networks, offer a ready-made channel for renewed product introductions, formulary listings, and co-branding opportunities.

Operational Footprint With a local head office in Saint-Hubert and a workforce concentrated in Canada, there is potential to tailor regional field sales,KOL engagement, and patient access programs to provincial health plans and hospital systems for faster adoption of new generics and biosimilars.

Sustainability & CSR Sustainable packaging initiatives and FSC certification partnerships point to a value proposition for purchasers prioritizing environmental, social, and governance criteria, enabling differentiated selling points in tender processes and sustainability-focused procurement.